Poly-ICLC

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study